Nearly one in five patients treated for acute dental infections receive high-risk clindamycin rather than safer first-line therapies, according to a study published late last week in Open Forum Infectious Diseases. Researchers examining more than 12,000 patient records across Michigan found that prescribing patterns frequently diverge from American Dental Association guidelines, exposing vulnerable populations to severe gastrointestinal complications.
Why Penicillin Remains the Standard Dental Treatment
- The First-Line Standard: The American Dental Association recommends penicillin-class antibiotics for most dental infections because they balance high bactericidal efficacy with a lower risk profile.
- The Clindamycin Hazard: Clindamycin carries a black box warning due to its strong association with Clostridioides difficile, a pathogen that causes severe, potentially fatal intestinal damage.
- The Allergy Misconception: Many patients receive alternative drugs due to charted penicillin allergies, but clinical data show true penicillin allergies are exceedingly rare in practice.
Michigan Health Network Study Reveals Prescribing Discrepancies
Acute dental pain drives nearly 2 million emergency department visits annually across the United States, CIDRAP reported. When definitive dental care is immediately unavailable, clinicians often rely on antimicrobial therapy to manage spreading inflammation in the jaw, ear, and neck. In the study analyzing records from the Trinity Health Michigan Network between January 2020 and August 2025, investigators found that 75% of patients properly received a penicillin-class medication. However, nearly 20% of participants walked out with a prescription for clindamycin.
Lisa Dumkow, senior author of the research, expressed disappointment at how frequently clinicians bypass safer options. “The majority of patients did not need clindamycin,” Dumkow told CIDRAP News. “They could have gotten an alternative antibiotic.” Before prescribing the drug, clinicians must recognize that “you have to literally be in a situation where you can’t use anything else.” The study included over 12,000 individuals, capturing care delivered primarily in urgent care facilities and emergency departments.
Allergy Misclassifications Drive High-Risk Drug Selections
Patient medical records in the study showed that more than 80% of individuals were encouraged to follow up with a dentist. Just over half of the participants received treatment in urgent care clinics, while 40% were managed in emergency departments and 8% by primary care doctors. Clinical decision-making was heavily influenced by reported penicillin allergies, which frequently turned out to be inaccurate upon closer evaluation.
Among patients who received an antibiotic other than penicillin, 21% had no documented allergy or intolerance, and 27% carried only a mild allergy or intolerance classification. Centers for Disease Control and Prevention data indicate that while 10% of the US population carries a charted penicillin allergy, less than 1% are genuinely allergic. The study noted that 35% of patients treated with clindamycin had reported very minor past reactions, such as mild to moderate rashes.
To reduce unnecessary reliance on high-risk alternatives, Dumkow encourages clinicians to screen patients using four targeted questions, such as evaluating whether a past reaction required medical intervention. If patients screen negative, the risk of a true adverse immunological response drops below 1%, allowing clinicians to safely administer a test dose under observation.
Efficacy Gaps and Treatment Failures in Emergency Settings
Beyond its well-documented safety hazards, clindamycin is losing clinical potency against oral pathogens. About 5% of patients in the study experienced treatment failure, requiring a secondary or alternative prescription within 30 days. Clindamycin demonstrated an 11% risk of treatment failure, marking the highest rate among all antibiotic classes evaluated in the analysis.
Erinne Kennedy, DDS, MPH, assistant dean for curriculum and learning at the Kansas City College of Dental Medicine, highlighted the broader utility of the findings. “This is a really great article that helps us understand the prescribing patterns that we’re seeing in emergency department visits,” said Kennedy, who was not involved in the research. She noted that regional data from bacterial sample analyses in Kansas similarly show that penicillin-class drugs outperform clindamycin in eliminating oral pathogens.
| Antibiotic Class | Prescribing Frequency (%) | Primary Clinical Risk / Outcome |
|---|---|---|
| Penicillin Class | 75% | Recommended first-line therapy; highest bactericidal efficacy |
| Clindamycin | ~20% | 11% treatment failure rate; black box warning for C. difficile |
Systemic Barriers to Definitive Dental Care
Experts emphasize that antimicrobial prescriptions serve only as a temporary measure rather than a definitive cure for deep-rooted tooth infections. Thomas Paumier, DDS, president of the American Dental Association, stressed that resolving the underlying pathology requires direct intervention in a dental office. “The correct treatment is a dental procedure, such as a root canal, which they aren’t doing in an urgent-care setting,” said Debra Goff, PharmD, a professor of pharmacy practice at The Ohio State University College of Pharmacy. “Antibiotics are the Band-Aid until definitive dental care can be given.”
Socioeconomic obstacles frequently prevent patients from accessing prompt dental procedures. Approximately 38% of individuals in the study lacked health insurance, and 27% relied on Medicaid. Even patients with coverage often face financial hurdles, as root canals and crowns can cost between $1,500 and $3,500, and many dental specialists decline insurance plans.
